Back to search

University of Washington

Cost-Utility Analysis of Medications for Relapsing-Remitting Multiple Sclerosis: A United States Third-Party Payer Perspective

Abstract

dc:description.abstract

Background: Many new disease-modifying therapies (DMTs) have recently been approved for relapsing-remitting multiple sclerosis (RRMS) in the United States. Objective: To assess the values of 10 first-line therapies for RRMS, including generic glatiramer acetate, versus the natural history of disease for a newly diagnosed RRMS patient. Perspective: United States third-party payer. Methods: A Markov model was developed and estimates were made using data on natural history of disease progression, annual relapse rates, medication efficacy, costs, and utilities to determine incremental cost-effectiveness ratios (ICERs). Results: Base case is a cohort of 30-year-old females at Extended Disability Status Scale (EDSS) state 0 at a 20 year time horizon versus the natural history of disease. Dimethyl fumarate demonstrates the lowest ICER at $895,073/QALY. Conclusions: DMTs for RRMS have low value versus the natural history of disease, and would not be considered cost-effective by conventional standards.

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Pistoresi, Ryan Hay
Advisor dc:contributor.advisor
  • Garrison, Louis P

Subjects

dc:subject × 5

Rights

dc:rights
Statement dc:rights
  • Copyright is held by the individual authors.
Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
http://hdl.handle.net/1773/33541

Chain of custody

source
Harvested from
University of Washington
Base URL
digital.lib.washington.edu/server/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Pistoresi, Ryan Hay. Cost-Utility Analysis of Medications for Relapsing-Remitting Multiple Sclerosis: A United States Third-Party Payer Perspective. 2015. http://hdl.handle.net/1773/33541